Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort

View/ Open
Use this link to cite
http://hdl.handle.net/2183/21786Collections
- Investigación (FCS) [1278]
Metadata
Show full item recordTitle
Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohortAuthor(s)
Date
2016-10Citation
Riveiro-Barcela M, Alonso S, Fernández I, et al. Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort. En: The 67th Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2016; 2016 Nov 11-15; Boston, Massachusetts. Hoboken, NJ: John Wiley & Sons; 2016. p. 464A (Heaptology. 2016; 64 Special issue 1)
Description
Poster abstract
Rights
This is the peer reviewed version of the article which has been published in final form at Hepatology. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving
ISSN
0270-9139